ArticleUrologic oncology2025
Rates of volume reduction after selective arterial embolization for renal angiomyolipoma.
Article in Urologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo characterize temporal patterns of renal angiomyolipoma volume reduction after selective arterial embolization and identify factors predictive of reduction rates MATERIALS AND
methodsRecords of patients undergoing renal angiomyolipoma embolization from July 2001 to July 2023 at our center were retrospectively reviewed. Tumor measurements were extracted from available imaging, and lipid content was scored based on tumor attenuation characteristics. Rates of volume reduction were compared for tumors at different follow-up intervals. The primary outcome was monthly tumor volume reduction.
resultsForty-four patients were identified who underwent 77 embolizations for 54 tumors. Of these, 32 patients had available volume data and were included in the analysis of our primary outcome. Tumor volumes decreased significantly faster during the first 6 months after embolization (7.4% per month) compared to years 2 and 3 of follow-up (0.3% per month, P = 0.01 and <0.1% per month, P = 0.01, respectively). Mean tumor size reduction within the first 6 months of initial embolization was 25% lower for patients who ultimately had repeat embolization compared to single-embolization patients. Within the first 6 months, older patients experienced 0.9% lower monthly volume reduction per additional year of age.
conclusionsEmbolized tumors in this cohort involuted rapidly during the first 6 months of follow-up, then stabilized, with the rate of volume reduction approaching 0% per month after 2 years. These data contribute to the understanding of angiomyolipoma embolization outcomes and may help providers avoid unnecessary embolization in patients with stable smaller tumors after 1 to 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.